1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,000 | 8,250 | 11:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.10. | WUXI XDC (02268): COMPLETION OF CONNECTED TRANSACTION INVOLVING SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 3 | HKEx | ||
| 15.10. | HSBC Research Continues to Favor Mainland CDMO Industry, Recommends Buying PHARMARON/WUXI XDC | 1 | AASTOCKS | ||
| 09.10. | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 9, 2025 | - | HKEx | ||
| 09.10. | WUXI XDC Slumps ~5% on Reported Shareholder STA Pharmaceutical's Stake Cut at 6.5% Discount | 1 | AASTOCKS | ||
| 26.09. | WUXI XDC (02268): INTERIM REPORT 2025 | 2 | HKEx | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 23.09. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF EXISTING CCT AGREEMENTS; AND ... | 3 | HKEx | ||
| 22.09. | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, OCTOBER 9, 2025 | 1 | HKEx | ||
| 22.09. | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 22.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.09. | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | 3 | HKEx | ||
| 10.09. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 03.09. | BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount | 5 | Bamboo Works | ||
| 03.09. | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 1 | HKEx | ||
| 03.09. | WUXI XDC (02268): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 02.09. | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAP FOR EXISTING PAYLOAD-LINKERS MASTER SERVICES AGREEMENT AND (2) RENEWAL ... | - | HKEx | ||
| 29.08. | HSBC startet Coverage für WuXi XDC mit "Buy" und sieht 37 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 29.08. | HSBC initiates WuXi XDC Cayman stock with Buy rating, sees 37% upside | 1 | Investing.com | ||
| 22.08. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| 18.08. | WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry | 113 | PR Newswire | - Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with its margin of 36.1%- Adjusted net profit before interest income and expense... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | 0,00 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | 0,00 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | 0,00 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| VENTYX BIOSCIENCES | 8,560 | 0,00 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | 0,00 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| BIONTECH | 92,35 | +2,38 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| QIAGEN | 40,490 | -0,66 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | 0,00 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | 0,00 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | 0,00 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data | ||
| PRIME MEDICINE | 4,950 | 0,00 % | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,000 Euro und damit -2,44 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.